Tokyo Tape
Sign in
← Sakai Chemical Industry

Quarterly report · Q2

4078.TEDINET S100S5CT
Period2023-04-01 → 2023-09-30
Filed2023-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥40.5bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥83.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥42.7bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥917m2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥3.3bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥885m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥4.6bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.8bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥773m2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥4.2bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥2.0bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.9bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥3.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥131.6bnat 2023-09-30Cons.Assets
Total assets¥128.0bnat 2023-03-31Cons.Assets
Total assets¥128.4bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥50.9bnat 2023-09-30Cons.Liabilities
Total liabilities¥43.3bnat 2023-03-31Cons.Liabilities
Net assets / equity¥80.7bnat 2023-09-30Cons.Net assets
Net assets / equity¥84.7bnat 2023-03-31Cons.Net assets
Net assets / equity¥85.8bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥15.6bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥12.4bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥15.5bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥12.2bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥11.7bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥10.5bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥3.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥773m2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥1.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥3.3bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-125.532023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-153.572023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥144.852022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥177.482022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥68.082022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio60.5%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio62.9%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio63.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥635m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥635m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.1bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2023-04-01 → 2023-09-30¥36.8bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2023-04-01 → 2023-09-30¥36.3bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥498m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.9bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2023-04-01 → 2023-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2023-04-01 → 2023-09-30¥4.2bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥136m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2023-04-01 → 2023-09-30¥144m
—segment totalrevenue2023-04-01 → 2023-09-30¥41.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥40.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥635m
—segment totalsegment profit2023-04-01 → 2023-09-30¥2.0bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥860m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥860m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥1.1bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2022-04-01 → 2022-09-30¥39.3bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2022-04-01 → 2022-09-30¥38.6bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥697m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2022-04-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥163m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2022-04-01 → 2022-09-30¥240m
—segment totalrevenue2022-04-01 → 2022-09-30¥43.6bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥42.7bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥860m
—segment totalsegment profit2022-04-01 → 2022-09-30¥4.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 522
ItemContextValueUnit
Interest and dividends income received ope cf inv cfPrior1YTDDuration92000000JPY
Interest and dividends income received ope cf inv cfCurrentYTDDuration82000000JPY
Interest expenses paid ope cf fin cfPrior1YTDDuration-38000000JPY
Interest expenses paid ope cf fin cfCurrentYTDDuration-53000000JPY
Proceeds from subsidy ope cfPrior1YTDDuration771000000JPY
Proceeds from subsidy ope cfCurrentYTDDuration－JPY
Proceeds from insurance income ope cfPrior1YTDDuration521000000JPY
Proceeds from insurance income ope cfCurrentYTDDuration－JPY
Income taxes paid ope cfPrior1YTDDuration-1795000000JPY
Income taxes paid ope cfCurrentYTDDuration-522000000JPY
Income taxes refund ope cfPrior1YTDDuration－JPY
Income taxes refund ope cfCurrentYTDDuration307000000JPY
Tender offer related expenses paid ope cfPrior1YTDDuration－JPY
Tender offer related expenses paid ope cfCurrentYTDDuration-342000000JPY
Net cash provided by used in operating activitiesPrior1YTDDuration1122000000JPY
Net cash provided by used in operating activitiesCurrentYTDDuration3187000000JPY
Purchase of property plant and equipment inv cfPrior1YTDDuration-1319000000JPY
Purchase of property plant and equipment inv cfCurrentYTDDuration-1646000000JPY
Proceeds from sales of property plant and equipment inv cfPrior1YTDDuration1000000JPY
Proceeds from sales of property plant and equipment inv cfCurrentYTDDuration0JPY
Purchase of investment securities inv cfPrior1YTDDuration-33000000JPY
Purchase of investment securities inv cfCurrentYTDDuration-12000000JPY
Proceeds from sales of investment securities inv cfPrior1YTDDuration181000000JPY
Proceeds from sales of investment securities inv cfCurrentYTDDuration60000000JPY
Other net inv cfPrior1YTDDuration-115000000JPY
Other net inv cfCurrentYTDDuration-27000000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-1285000000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration-1625000000JPY
Net increase decrease in short term loans payable fin cfPrior1YTDDuration2569000000JPY
Net increase decrease in short term loans payable fin cfCurrentYTDDuration-1191000000JPY
Proceeds from long term loans payable fin cfPrior1YTDDuration－JPY
Proceeds from long term loans payable fin cfCurrentYTDDuration4500000000JPY
Repayment of long term loans payable fin cfPrior1YTDDuration-949000000JPY
Repayment of long term loans payable fin cfCurrentYTDDuration-1604000000JPY
Proceeds from issuance of convertible bond type new stock reservation rights attached corporate bond fin cfPrior1YTDDuration－JPY
Proceeds from issuance of convertible bond type new stock reservation rights attached corporate bond fin cfCurrentYTDDuration3000000000JPY
Purchase of treasury stock fin cfPrior1YTDDuration-0JPY
Purchase of treasury stock fin cfCurrentYTDDuration-0JPY
Cash dividends paid fin cfPrior1YTDDuration-565000000JPY
Cash dividends paid fin cfCurrentYTDDuration-485000000JPY
Dividends paid to non controlling interests fin cfPrior1YTDDuration-48000000JPY
Dividends paid to non controlling interests fin cfCurrentYTDDuration-33000000JPY
Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cfPrior1YTDDuration-0JPY
Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cfCurrentYTDDuration-2631000000JPY
Other net fin cfPrior1YTDDuration－JPY
Other net fin cfCurrentYTDDuration35000000JPY
Net cash provided by used in financing activitiesPrior1YTDDuration1006000000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration1587000000JPY
Effect of exchange rate change on cash and cash equivalentsPrior1YTDDuration274000000JPY
Effect of exchange rate change on cash and cash equivalentsCurrentYTDDuration186000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass